Cargando…

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial

Disclosure, or open communication, by female microbicide trial participants of their trial participation and use of an investigational HIV prevention drug to a sexual partner may affect participants' trial product usage behavior and contribute to poor adherence. With mixed results from recent m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Succop, Stacey M., MacQueen, Kathleen M., van Loggerenberg, Francois, Majola, Nelisile, Karim, Quarraisha Abdool, Karim, Salim S. Abdool
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193265/ https://www.ncbi.nlm.nih.gov/pubmed/25285564 http://dx.doi.org/10.1080/09540121.2014.938014

Ejemplares similares

Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study
por: MacQueen, Kathleen M., et al.
Publicado: (2014)

Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012)

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
por: Karim, Quarraisha Abdool, et al.
Publicado: (2011)

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
por: Matthews, Lynn T., et al.
Publicado: (2013)

No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
por: Chopera, Denis R., et al.
Publicado: (2013)

Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa
por: MacQueen, Kathleen M., et al.
Publicado: (2016)

Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004
por: Castor, Delivette, et al.
Publicado: (2022)

Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study
por: van Loggerenberg, Francois, et al.
Publicado: (2008)

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide
por: Ngandu, Nobubelo K., et al.
Publicado: (2017)

CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
por: Gengiah, Tanuja Narayansamy, et al.
Publicado: (2022)

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
por: McKinnon, Lyle R., et al.
Publicado: (2018)

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial
por: Mansoor, Leila E, et al.
Publicado: (2014)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
por: Baxter, Cheryl, et al.
Publicado: (2019)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
por: Archary, D, et al.
Publicado: (2016)

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
por: Mahomed, Sharana, et al.
Publicado: (2020)

Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
por: Baxter, Cheryl, et al.
Publicado: (2021)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

Current status of the HIV epidemic & challenges in prevention
por: Karim, Quarraisha Abdool
Publicado: (2017)

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
por: Mahomed, Sharana, et al.
Publicado: (2023)

Mechanisms of sexually transmitted infection‐induced inflammation in women: implications for HIV risk
por: Mwatelah, Ruth, et al.
Publicado: (2019)

Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection
por: Naranbhai, Vivek, et al.
Publicado: (2013)

Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel
por: Chirenje, Zvavahera M, et al.
Publicado: (2012)

Inclusion of adolescent girls in HIV prevention research – an imperative for an AIDS-free generation
por: Karim, Quarraisha Abdool, et al.
Publicado: (2014)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
por: Abdool Karim, Quarraisha, et al.
Publicado: (2022)

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
por: Mahomed, Sharana, et al.
Publicado: (2019)

Enhancing oral PrEP uptake among adolescent girls and young women in Africa
por: Heck, Craig J., et al.
Publicado: (2022)

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
por: Mahomed, Sharana, et al.
Publicado: (2020)

Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa
por: Singh, Jerome Amir, et al.
Publicado: (2006)

HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services
por: Kharsany, Ayesha BM, et al.
Publicado: (2012)

Honing in on enteric fever
por: McKinnon, Lyle R, et al.
Publicado: (2014)

Low adverse event rates following voluntary medical male circumcision in a high HIV disease burden public sector prevention programme in South Africa
por: Phili, Rogerio, et al.
Publicado: (2014)

Putting women in the centre of the global HIV response is key to achieving epidemic control!
por: Abdool Karim, Quarraisha, et al.
Publicado: (2020)

Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage
por: Archary, Derseree, et al.
Publicado: (2015)

Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy
por: Naranbhai, Vivek, et al.
Publicado: (2014)

ARV-based HIV prevention for women – where we are in 2014
por: Mastro, Timothy D, et al.
Publicado: (2014)

Adolescent girls and young women: key populations for HIV epidemic control
por: Dellar, Rachael C, et al.
Publicado: (2015)

Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa
por: Ayton, Sarah Gabrielle, et al.
Publicado: (2020)

Mucosal effects of tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women
por: Joag, Vineet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0pkonurcuf1egri6hvltrchfu8